ZyVersa Therapeutics (ZVSA) Forms New Scientific Advisory Board

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces a new SAB to support advancement of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications. Based on its mechanism of action, IC 100, in combination with incretin therapy, is anticipated to augment weight loss, but more importantly, to attenuate the chronic systemic inflammation leading to metabolic complications and other inflammatory comorbidities of obesity.

“We are honored to work with such an accomplished and esteemed group of experts,” stated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President. “Our advisors’ combined expertise and insights in the areas of obesity, metabolic diseases, and inflammasomes will be invaluable as we design IC 100’s clinical development program for obesity and metabolic complications.”

Members of ZyVersa’s Obesity, Metabolic and Inflammatory Diseases SAB are listed below. Full biographies are available on ZyVersa's Website.

Caroline M. Apovian, MD, FACP, FTOS, DABOM

• Co-Director, Center for Weight Management and Wellness, Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women’s Hospital
• Professor of Medicine, Harvard Medical School

Harold Bays, MD, MFOMA, FTOS, FACC, FACE, FNLA, FASPC

• Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center
• Clinical Associate Professor, Endocrinology, University of Louisville School of Medicine
• Chief Science Officer of the Obesity Medicine Association

Helen Bramlett, PhD

• Professor, Department of Neurological Surgery, University of Miami Miller School of Medicine
• The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine

Marc-Andre Cornier, MD

• Professor of Medicine, Medical University of South Carolina
• Director, Division of Endocrinology, Diabetes and Metabolic Diseases, Medical University of South Carolina

Juan Pablo de Rivero Vaccari, PhD

• Associate Professor, Department of Neurological Surgery, University of Miami Miller School of Medicine
• The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine
• Distinguished Faculty Member, the Center for Cognitive Neuroscience and Aging, University of Miami Miller School of Medicine

W. Dalton Dietrich, III, PhD

• Kinetic Concepts Distinguished Chair in Neurosurgery, and Scientific Director,
• The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine
• Senior Associate Dean for Discovery Science and Co-Director, the Institute for Neural Engineering, University of Miami Miller School of Medicine
• Professor, Neurological Surgery, Neurology, Biomedical Engineering, and Cell Biology, University of Miami Miller School of Medicine

Robert W. Keane, PhD

• Professor, Physiology and Biophysics, Neurological Surgery and Microbiology, and Immunology, University of Miami Miller School of Medicine
• The Miami Project to Cure Paralysis. University of Miami Miller School of Medicine

Samuel Klein, MD

• William H. Danforth Professor of Medicine, Washington University School of Medicine
• Director, Center for Human Nutrition, Washington University School of Medicine
• Chief, Division of Nutritional Science and Obesity Medicine, Washington University School of Medicine

Suneil Koliwad, MD, PhD

• Chief, Division of Endocrinology and Metabolism, UCSF Health
• Gerold Grodsky Professor of Diabetes Research, UCSF
• Mount Zion Health Fund Distinguished Professor of Endocrinology, UCSF

You May Also Be Interested In

• Axon adds two independent directors to its board
• Peapack Private names Paul Kotronis as senior CRE director
• Ideal Power (IPWR) files $75M mixed shelf